Virological Outcome and Management of Persistent Low-Level Viraemia in HIV-1-Infected Patients: 11 Years of the Swiss HIV Cohort Study

Abstract

Background

Management of persistent low-level viraemia (pLLV) in patients on combined antiretroviral therapy (cART) with previously undetectable HIV viral loads (VLs) is challenging. We examined virological outcome and management among patients enrolled in the Swiss HIV Cohort Study (SHCS).

Methods

In this retrospective study (2000–2011), pLLV was defined as a VL of 21–400 copies/ml on ≥ three consecutive plasma samples with ≥8 weeks between first and last analyses, in patients undetectable for ≥24 weeks on cART. Control patients had ≥ three consecutive undetectable VLs over ≥32 weeks. Virological failure (VF), analysed in the pLLV patient group, was defined as a VL>400 copies/ml.

Results

Among 9,972 patients, 179 had pLLV and 5,389 were controls. Compared to controls, pLLV patients were more often on unboosted protease inhibitor (PI)-based (adjusted odds ratio [aOR; 95% CI] 3.2 [1.8, 5.9]) and nucleoside/nucleotide reverse transcriptase inhibitor (NRTI)-only combinations (aOR 2.1 [1.1, 4.2]) than on non-nucleoside reverse transcriptase inhibitor and boosted PI-based regimens. At 48 weeks, 102/155 pLLV patients (66%) still had pLLV, 19/155 (12%) developed VF and 34/155 (22%) had undetectable VLs. Predictors of VF were previous VF (aOR 35 [3.8, 315]), unboosted PI-based (aOR 12.8 [1.7, 96]) or NRTI-only combinations (aOR 115 [6.8, 1,952]), and VLs>200 during pLLV (aOR 3.7 [1.1, 12]). No VF occurred in patients with persistent very LLV (21-49 copies/ml; n=26). At 48 weeks, 29/39 patients (74%) who changed cART had undetectable VLs, compared with 19/74 (26%) without change (P <0.001).

Conclusions

Among patients with pLLV, VF was predicted by previous VF, cART regimen and VL≥200. Most patients who changed cART had undetectable VLs 48 weeks later. These findings support cART modification for pLLV>200 copies/ml.

References

Murray

J.S.

, Elashoff

M.R.

, Iacono-Connors

L.C.

, Cvetkovich

T.A.

, Struble

K.A.

The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs.

AIDS 1999; 13: 797–804.

Mellors

J.W.

, Munoz

, Giorgi

J.V.

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.

Ann Intern Med 1997; 126: 946–954.

Sungkanuparph

, Groger

R.K.

, Overton

E.T.

, Fraser

V.J.

, Powderly

W.G.

Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy.

HIV Med 2006; 7: 437–441.

Cohen

Low-level viremia in HIV-1 infection: consequences and implications for switching to a new regimen.

HIV Clin Trials 2009; 10: 116–124.

Thompson

M.A.

, Aberg

J.A.

, Cahn

Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel.

JAMA 2010; 304: 321–333.

Widdrington

, Payne

, Medhi

, Valappil

, Schmid

M.L.

The significance of very low-level viraemia detected by sensitive viral load assays in HIV infected patients on HAART.

J Infect 2011; 62: 87–92.

Greub

, Cozzi-Lepri

, Ledergerber

Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy.

AIDS 2002; 16: 1967–1969.

J.Z.

, Gallien

, Do

T.D.

Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia.

Antimicrob Agents Chemother 2012; 56: 5998–6000.

Nettles

R.E.

, Kieffer

T.L.

, Simmons

R.P.

Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy.

Clin Infect Dis 2004; 39: 1030–1037.

10.

Doyle

, Smith

, Vitiello

Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy.

Clin Infect Dis 2012; 54: 724–732.

11.

Henrich

T.J.

, Wood

B.R.

, Kuritzkes

D.R.

Increased risk of virologic rebound in patients on antiviral therapy with a detectable HIV load <48 copies/mL.

PLoS ONE 2012; 7: e50065.

12.

Laprise

, de Pokomandy

, Baril

J.G.

, Dufresne

, Trottier

Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation.

Clin Infect Dis 2013; 57: 1489–1496.

13.

Maggiolo

, Callegaro

, Cologni

Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure.

J Acquir Immune Defic Syndr 2012; 60: 473–482.

14.

Charpentier

, Landman

, Laouenan

Persistent low-level HIV-1 RNA between 20 and 50 copies/ml in antiretroviral-treated patients: associated factors and virological outcome.

J Antimicrob Chemother 2012; 67: 2231–2235.

15.

Deeks

S.G.

, Martin

J.N.

, Sinclair

Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1.

J Infect Dis 2004; 189: 312–321.

16.

Delaugerre

, Gallien

, Flandre

Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients.

PLoS ONE 2012; 7: e36673.

17.

Dinoso

J.B.

, Kim

S.Y.

, Wiegand

A.M.

Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy.

Proc Natl Acad Sci U S A 2009; 106: 9403–9408.

18.

Gandhi

R.T.

, Zheng

, Bosch

R.J.

The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial.

PLoS Med 2010; 7: e1000321.

19.

García-Gascó

, Maida

, Blanco

Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome.

J Antimicrob Chemother 2008; 61: 699–704.

20.

Günthard

H.F.

, Wong

J.K.

, Ignacio

C.C.

Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy.

J Virol 1998; 72: 2422–2428.

21.

Hermankova

, Ray

S.C.

, Ruff

HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy.

JAMA 2001; 286: 196–207.

22.

Joos

, Fischer

, Kuster

HIV rebounds from latently infected cells, rather than from continuing low-level replication.

Proc Natl Acad Sci U S A 2008; 105: 16725–16730.

23.

Lo Re

III , Gasink

, Kostman

J.R.

, Leonard

, Gross

Natural history of patients with low-level HIV viremia on antiretroviral therapy.

AIDS Patient Care STDS 2004; 18: 436–442.

24.

Ostrowski

S.R.

, Katzenstein

T.L.

, Thim

P.T.

, Pedersen

B.K.

, Gerstoft

, Ullum

Low-level viremia and proviral DNA impede immune reconstitution in HIV-1-infected patients receiving highly active antiretroviral therapy.

J Infect Dis 2005; 191: 348–357.

25.

Pham

, Alrabaa

, Somboonwit

, Le

, Montero

The HIV virologic outcomes of different interventions among treatment-experienced patients with 2 consecutive detectable low-level viremia.

J Int Assoc Physicians AIDS Care (Chic) 2011; 10: 54–56.

26.

Taiwo

, Gallien

, Aga

Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy.

J Infect Dis 2011; 204: 515–520.

27.

Günthard

H.F.

, Frost

S.D.

, Leigh-Brown

A.J.

Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy.

J Virol 1999; 73: 9404–9412.

28.

Thompson

M.A.

, Aberg

J.A.

, Hoy

J.F.

Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.

JAMA 2012; 308: 387–402.

29.

DHHS-panel. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. (Accessed 11 April 2014.) Available from http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.

30.

Hirsch

M.S.

, Gunthard

H.F.

, Schapiro

J.M.

Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.

Clin Infect Dis 2008; 47: 266–285.

31.

Schoeni-Affolter

, Ledergerber

, Rickenbach

Cohort Profile: the Swiss HIV Cohort Study.

Int J Epidemiol 2010; 39: 1179–1189.

32.

Fayet Mello

, Buclin

, Decosterd

L.A.

Successful efavirenz dose reduction guided by therapeutic drug monitoring.

Antivir Ther 2011; 16: 189–197.

33.

Stanford HIV drug resistance database. (Accessed 11 April 2014.) Available from http://hivdb.stanford.edu.

34.

Glass

T.R.

, De Geest

, Hirschel

Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients.

Antivir Ther 2008; 13: 77–85.

35.

Elzi

, Marzolini

, Furrer

Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.

Arch Intern Med 2010; 170: 57–65.

36.

Opravil

, Sereni

Natural history of HIV-associated pulmonary arterial hypertension: trends in the HAART era.

AIDS 2008; 22 Suppl 3: S35–S40.

37.

Malan

D.R.

, Krantz

, David

Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients.

J Acquir Immune Defic Syndr 2008; 47: 161–167.

38.

Maggiolo

, Callegaro

, Cologni

Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure.

J Acquir Immune Defic Syndr 2012; 60: 473–482.

39.

Doyle

, Geretti

A.M.

Low-level viraemia on HAART: significance and management.

Curr Opin Infect Dis 2012; 25: 17–25.

40.

Boillat-Blanco

, Darling

K.E.

, Taffe

Impact of recommendation updates in well-controlled patients on nonrecommended antiretroviral therapies: the Swiss HIV cohort study.

J Acquir Immune Defic Syndr 2013; 62: 180–189.

41.

Yeni

P.G.

, Hammer

S.M.

, Hirsch

M.S.

Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

JAMA 2004; 292: 251–265.

42.

Swiss HIV Cohort Study, Schoeni-Affolter

, Ledergerber

Cohort profile: the Swiss HIV Cohort study.

Int J Epidemiol 2010; 39: 1179–1189.